Nummular Eczema — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for nummular eczema. 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
8
Active US patents
50/100
Avg vulnerability
—
Annual revenue covered

Originators in Nummular Eczema

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Fougera Pharms 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating nummular eczema. Each bar = one year. Y-axis scaled to peak year (4 patents).

1
28
4
30
1
35
2
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Temovate
CLOBETASOL PROPIONATE
 Fougera Pharms 8 50 — 2028-11-05

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11179465 Temovate method of use 64 2030-08-31
8460641 Temovate method of use 63 2028-11-05
11376262 Temovate method of use 58 2036-05-09
10588914 Temovate method of use 51 2030-08-31
10064875 Temovate method of use 51 2030-08-31
9956231 Temovate method of use 51 2030-08-31
10588913 Temovate formulation 38 2036-05-09
9855334 Temovate formulation 25 2035-03-11

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9855334 Temovate formulation 25 2035-03-11
10588913 Temovate formulation 38 2036-05-09
9956231 Temovate method of use 51 2030-08-31
10588914 Temovate method of use 51 2030-08-31
10064875 Temovate method of use 51 2030-08-31
11376262 Temovate method of use 58 2036-05-09
8460641 Temovate method of use 63 2028-11-05
11179465 Temovate method of use 64 2030-08-31

Related